Skip to main content

Table 4 Comparisons of impacted genes and called variants across clinical IHC subtypes. Only breast cancers with at least one variant were counted

From: Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses

Subtype

Mutation type

Mean

SD

Min

Max

HR+/HER2+

Impacted genes

1.7

0.7

1

4

Called variants

2.2

1.4

1

7

HR+/HER2-

Impacted genes

1.3

0.6

1

4

Called variants

3.4

11.2

1

96

HR−/HER2+

Impacted genes

1.8*

0.6

1

3

Called variants

9.4*

21.9

1

80

HR−/HER2-

Impacted genes

1.3

0.6

1

3

Called variants

6.4

10.5

1

32

  1. (*P < 0.01)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us